metricas
covid
Buscar en
Enfermedades Infecciosas y Microbiología Clínica
Toda la web
Inicio Enfermedades Infecciosas y Microbiología Clínica Evolución de la sensibilidad de 235 cepas de Helicobacter pylori entre 1995 y 1...
Journal Information
Vol. 20. Issue 4.
Pages 157-160 (April 2002)
Share
Share
Download PDF
More article options
Vol. 20. Issue 4.
Pages 157-160 (April 2002)
Full text access
Evolución de la sensibilidad de 235 cepas de Helicobacter pylori entre 1995 y 1998 e impacto del tratamiento antibiótico
Sensitivity of 235 strains of Helicobacter pylori from 1995 to 1998 and impact of antibiotic treatment
Visits
4618
Eva Cuchí Burgosa,1
Corresponding author
micro@mutuaterrassa.es

Correspondencia: Dra. E. Cuchí Burgos. Servicio de Microbiología. Hospital Mútua de Terrassa. García Humet, 2. 08221 Terrassa. Barcelona.
, Montserrat Forné Barderab, Salvador Quintana Rierac, José Lite Litea, Javier Garau Alemanyc
a Servicio de Microbiología
b Servicio de Gastroenterología
c Servicio de Medicina Interna. Hospital Mútua de Terrassa. Barcelona. España
This item has received
Article information
Fundamento

Conocer la sensibilidad de Helicobacter pylori a los antibióticos utilizados en el tratamiento erradicador, su evolución temporal y la influencia de la utilización previa de dicho tratamiento.

Material y métodos

Se estudió mediante E-test la sensibilidad a amoxicilina, metronidazol, claritromicina y tetraciclina de 235 aislamientos consecutivos de Helicobacter pylori durante el período comprendido entre 1995 y 1998, y se relacionaron los valores de concentración mínima inhibitoria (CMI) hallados con la utilización previa de tratamiento erradicador.

Resultados

Se observó un porcentaje de resistencia a metronidazol de 23,5%, de 12,9% a claritromicina y de 0,7% a tetraciclina; ninguna de las cepas fue resistente a amoxicilina. No se observaron cambios significativos en los porcentajes de resistencia a lo largo del período estudiado. Los porcentajes de resistencia a metronidazol y claritromicina fueron significativamente más elevados (p _ 0,03 y p < 0,001, respectivamente) en las cepas aisladas de los pacientes que habían recibido tratamiento.

Conclusiones

Es necesaria la monitorización de la sensibilidad de H. pylori a los antibióticos utilizados en el tratamiento erradicador, especialmente en los pacientes previamente tratados.

Palabras clave:
Helicobacter pylori
Sensibilidad antibiótica
Tratamiento
Background

The aim of this study was to investigate the sensitivity of Helicobacter pylori to the antibiotics used in its eradication over a period of four years and to determine the influence of previous treatment on sensitivity.

Material and methods

During the period from 1995 to 1998 we determined the sensitivity of 235 consecutive Helicobacter pylori isolates to amoxicillin, metronidazole, clarythromycin and tetracycline by means of E-test methodology. The MIC values found were related with the prior use of eradicating treatment.

Results

The percentage of resistant strains were as follows: 23.5% to metronidazole, 12.9% to clarythromycin and 0.7% to tetracycline; none of the strains was resistant to amoxicillin. There were no significant changes in percentage of resistance to the drugs studied over the 4-year period. Resistance to metronidazole and clarythromycin was significantly higher (p _ 0.03 and p < 0.001 respectively) in strains isolated from patients who had received previous treatment.

Conclusions

Monitorization of H. pylori sensitivity to the drugs used in its eradication is particularly important in patients who have undergone prior treatment.

Key words:
Helicobacter pylori
Antibiotic susceptibility
Treatment
Full text is only aviable in PDF
Bibliografía
[1.]
J.R. Warren, B.J. Marshall.
Unidentified curved bacilli on gastric epithelium in active chronic gastritis.
Lancet, 1 (1983), pp. 1273-1275
[2.]
F. Lerang, B. Moum, E. Ragnhildsveit, P.K. Sandvei, P. Tolas, J.E. Whist, et al.
Simplified 10-day bismuth triple therapy for cure of Helicobacter pylori infection: Experience from clinical practice in a population with a high frequency of metronidazole resistance.
Am J Gastroenterol, 93 (1998), pp. 212-216
[3.]
National Committee for Clinical Laboratory Standards..
Performance Standards for Antimicrobial Susceptibility Testing;Ninth Informational Supplement M100-S9 (1999), NCCLS, (1999),
[4.]
G. Cederbrant, G. Kahlmeter, A. Ljungh.
The E test for antimicrobial susceptibility testing of Helicobacter pylori, 31 (1993), pp. 65-71
[5.]
S. Hartvig Hartzen, L. Percival Andersen, A. Bremmelgaard, H. Colding, M. Arpi, J. Kristiansen, et al.
Antimicrobial susceptibility testing of 230 Helicobacter pylori strains: Importance of medium, inoculum and incubation time.
Antimicrob Agents Chemother, 41 (1997), pp. 2634-2639
[6.]
T. Alarcon, D. Domingo, M. Lopez-Brea.
Discrepancies between E-Test and agar dilution methods for testing metronidazole susceptibility of Helicobacter pylori.
J Clin Microbiol, 36 (1998), pp. 1165-1166
[7.]
R. Piccolimini, G. Di Bonaventura, G. Catamo, F. Carbone, M. Neri.
Comparative evaluation of the E Test, agar dilution, and broth microdilution for testing susceptibilities of Helicobacter pylori strains to 20 antimicrobial agents.
J Clin Microbiol, 35 (1997), pp. 1842-1846
[8.]
M.R. Iovene, M. Romano, A.P. Pilloni, B. Giordano, F. Montella, S. Caliendo, et al.
Prevalence of antimicrobial resistance in eighty clinical isolates of Helicobacter pylori.
Chemotherapy, 45 (1999), pp. 8-14
[9.]
S. Chaves, M. Gadanho, R. Tenreiro, J. Cabrita.
Assessment of metronidazole susceptibility in Helicobacter pylori: Statistical validation and error rate analysis of breakpoints determined with the disk diffusion test.
J Clin Microbiol, 37 (1999), pp. 1628-1631
[10.]
A.A. van Zwet, C.M.J.E. Vandenbrouke-Grauls, J.C. Thijs, E.J. Van der Wouden, M.M. Gerrits, J.G. Kusters.
Stable amoxicillin resistance in Helicobacter pylori.
[11.]
M.P. Dore, M.S. Osato, G. Realdi, I. Mura, D.Y. Graham, A.R. Sepulveda.
J Antimicrob Chemother, 43 (1999), pp. 47-54
[12.]
O. López Bartolomé, A. Morán Vasallo, J.A. Ramírez Armengol, J.J. Picazo de la Garza.
Diagnóstico microbiológico de Helicobacter pylori y su resistencia a los antimicrobianos.
Rev Clin Esp, 198 (1998), pp. 420-423
[13.]
M. Lopez-Brea, D. Domingo, I. Sanchez, T. Alarcon.
Evolution of resistance to metronidazole and clarithromycin in Helicobacter pylori clinical isolates in Spain.
J Antimicrob Chemother, 40 (1997), pp. 279-281
[14.]
K. Wolle, M. Nilius, A. Leodolter, W.A. Müller, P. Malfertheiner, W. König.
Prevalence of Helicobacter pylori resistance to several antimicrobial agents in a region of Germany.
Eur J Clin Microbiol Infect Dis, 17 (1998), pp. 519-521
[15.]
H. Xia, M. Buckley, C.T. Keane, C.A. O’Morain.
Clarithromycin resistance in Helicobacter pylori: Prevalence in untreated dyspeptic patients and stability in vitro.
J Antimicrob Chemother, 37 (1996), pp. 473-481
[16.]
European Study Group on Antibiotic Susceptibility of Helicobacter pylori. Results of a multicentre European survey in 1991 of metronidazole resistance in Helicobacter pylori.
Eur J Clinical Microbiol Infect Dis, 11 (1992), pp. 777-781
[17.]
G.V. Loo, C.A. Fallone, E. De Souza, J. Lavallée, A.N. Barkun.
In-vitro susceptibility of Helicobacter pylori to ampicillin, clarithromycin, metronidazole and omeprazole.
J Antimicrob Chemother, 40 (1997), pp. 881-883
[18.]
J.P. Gisbert, D. Boixeda, L. Rafael de, C. Redondo, C. Martín de Argila, F. Bermejo.
¿De qué factores depende el éxito de la triple terapia “clásica” en la erradicación de Helicobacter pylori?.
Rev Esp Enferm Dig, 88 (1996), pp. 317-322
[19.]
A. Gotoh, Y. Kawakami, T. Akahane, T. Akamatsu, T. Shimizu, K. Kiyosawa, et al.
Susceptibility of Helicobacter pylori isolates against agents commonly administered for eradication therapy and the efficacy of chemotherapy.
Microbiol Immunol, 41 (1997), pp. 7-12
[20.]
Y. Glupczynski, S. Goutier, C. Van der Borre, J.P. Butzler, A. Burette.
Surveillance of Helicobacter pylori resistance to antimicrobial agents in Belgium from 1989 to 1994.
Gut, 37 (1995), pp. A56
[21.]
M. Sörberg, H. Hanberger, M. Nilsson, A. Bjorkman, N.E. Lennart.
Risk of development of in vitro resistance to amoxicillin, clarithromycin, and metronidazole in Helicobacter pylori.
Antimicrob Agents Chemother, 42 (1998), pp. 1222-1228
[22.]
P.D. Midolo, M.G. Korman, J.D. Turnidge, J.R. Lambert.
Helicobacter pylori resistance to tetracycline.
Lancet, 347 (1996), pp. 1194-1195
[23.]
W.A. de Boer, G.N.J. Tytgat.
How to treat Helicobacter pylori infection - should treatment strategies be based on testing bacterial susceptibility? A personal viewpoint.
Eur J Gastroenterol Hepatol, 8 (1996), pp. 709-716
[24.]
T. Breuer, D.Y. Graham.
Costs of diagnosis and treatment of Helicobacter pylori infection: When does choosing the treatment regimen based on susceptibility testing become cost effective?.
Am J Gastroenterol, 94 (1999), pp. 725-729
[25.]
C.K. Ching, K.P. Leung, R.W.H. Yung, S.K. Lam, B.C.Y. Wong, K.C. Lai, C.L. Lai.
Prevalence of metronidazole resistant Helicobacter pylori strains among Chinese peptic ulcer disease patients and normal controls in Hong Kong.
Gut, 38 (1996), pp. 675-678
[26.]
H.X. Xia, M. Buckley, D. Hyde, C.T. Keane, C.A. O’Morain.
Effects of antibiotic resistance on clarithromycin combined triple therapy for Helicobacter pylori.
Gut, 37 (1995), pp. 55
[27.]
J.P. Gisbert, J.M. Pajares.
Resistencia de Helicobacter pylori al metronidazol y a la claritromicina en España. Una revisión sistemática.
Med Clin (Barc), 116 (2001), pp. 111-116
[28.]
C.L. Williams.
Helicobacter pylori: Bacteriology and laboratory diagnosis.
J Infect, 34 (1997), pp. 1-5
[29.]
F. Mégraud, N. Lehn, T. Lind, E. Bayerdörffer, C. O’Morain, R. Spiller, et al.
Antimicrobial susceptibility testing of Helicobacter pylori in a large multicenter trial: The MACH 2 Study.
Antimicrob Agents Chemother, 43 (1999), pp. 2747-2752
Copyright © 2002. Elsevier España, S.L.. Todos los derechos reservados
Download PDF
Article options
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos